Navigation Links
Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Date:3/31/2009

CORONA, Calif., March 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the District of Delaware has ruled that Watson's generic version of Concerta (methylphenidate hydrochloride extended-release tablets) does not infringe United States Patent No. 6,919,373 (the '373 Patent) and that the '373 Patent is invalid. The opinion, dated March 30, 2009, was issued by Judge Joseph Farnan, Jr., and applies to Watson's generic versions of Concerta(R) in the 18 mg, 27 mg, 36 mg and 54 mg strengths.

Prior to the commencement of the trial, the plaintiffs offered Watson a covenant not to sue on United States Patent No. 6,930,129 (the '129 Patent). Watson declined to accept the covenant and asked the court to declare that the '129 Patent is invalid and not infringed. A decision on Watson's Declaratory Judgment claim on the '129 Patent is subject to further proceedings by the parties. However, Watson believes that the '129 Patent is invalid for the same reasons that the court held the '373 Patent is invalid.

"We are very pleased that the court has ruled in our favor and we will continue to evaluate the court's opinion as we contemplate next steps," said Paul Bisaro, Watson's President and Chief Executive Officer. "We are currently pursuing final FDA approval of this important product."

In 2005, ALZA Corporation and McNeil-PPC, Inc. sued Andrx Corporation for patent infringement related to the generic version of Concerta(R). Watson acquired Andrx Corporation in 2006.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical pr
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
4. Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute
5. Delaware Man Spearheads Brain Tumor Awareness
6. DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership
7. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
8. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
9. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
10. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
11. Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Scientists are using the engineering technology behind the ... models for the replacement of delicate and complex ... The researchers, combining engineering and plastic ... topological optimization to design an experimental 3-D structure ...
... IRVINE, Calif. , July 12 ... the development and commercialization of personalized DNA-based diagnostics ... completed license agreements with key Norwegian cancer researchers. ... promising genomic technologies with the intention of developing ...
... , July 12, 2010 Points to,Novel Pathway for Drug ... Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic ... and North America today,report the discovery of a common ...
Cached Biology Technology:High-performance engineering used to design facial bone replacements 2High-performance engineering used to design facial bone replacements 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 2OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 4deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... have developed a new method for delivering molecules ... the cell surface. The technique could find applications ... fields. , Bulk electroporation a technique used ... in the cell membrane that are caused by ... increasingly popular method of cell transfection. (Cell transfection ...
(Date:5/21/2013)... the University of Illinois at Chicago College of Medicine will ... fat -- its main energy source -- and how changes ... a new $2 million, 4-year grant from the National Heart, ... how it uses fuel for energy. These changes may play ... are different in men and women, says E. Douglas Lewandowski, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... a gas they also produce naturally as a hormone, the result ... and fading in the case of flowers all of which ... plants with products available in the market today, such as EthylBloc ... for fruits and vegetables, that contain a compound that blocks ...
... mechanism of action of genes has been hampered by the ... is true for even the most common class of cancer-associated ... events in cells by phosphorylating and modulating the activity of ... efforts that up to a quarter of kinases may play ...
... TAMPA, Fla., May 1 Stinger Systems, Inc. ... today announced,that it had reached a settlement agreement ... Inc. said it settled the matter without admitting ... barring future,violations. Stinger Systems, Inc. also said that ...
Cached Biology News:A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 2A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 3
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... a new technology for sensitive detection ... amounts of DNA (5). This process ... modify the DNA, followed by PCR ... distinguish methylated from unmethylated DNA. The ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: